Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
Tomas Kalincik,Sifat Sharmin,Izanne Roos,Mark S Freedman,Harold Atkins,Joachim Burman,Jennifer Massey,Ian Sutton,Barbara Withers,Richard Macdonell,Andrew Grigg,Øivind Torkildsen,Lars Bo,Anne Kristine Lehmann,Eva Kubala Havrdova,Eva Krasulova,Marek Trnený,Tomas Kozak,Anneke van der Walt,Helmut Butzkueven,Pamela McCombe,Olga Skibina,Jeannette Lechner-Scott,Barbara Willekens,Elisabetta Cartechini,Serkan Ozakbas,Raed Alroughani,Jens Kuhle,Francesco Patti,Pierre Duquette,Alessandra Lugaresi,Samia J Khoury,Mark Slee,Recai Turkoglu,Suzanne Hodgkinson,Nevin John,Davide Maimone,Maria Jose Sa,Vincent van Pesch,Oliver Gerlach,Guy Laureys,Liesbeth Van Hijfte,Rana Karabudak,Daniele Spitaleri,Tunde Csepany,Riadh Gouider,Tamara Castillo-Triviño,Bruce Taylor,Basil Sharrack,John A Snowden,MSBase Study Group Collaborators,MSBase Study Group Authors,Saloua Mrabet,Justin Garber,Jose Luis Sanchez-Menoyo,Eduardo Aguera-Morales,Yolanda Blanco,Abdullah Al-Asmi,Bianca Weinstock-Guttman,Yara Fragoso,Koen de Gans,Allan Kermode,MSBase Study Group,Dana Horakova,Katherine Buzzard,Murat Terzi,Alexandre Prat,Marc Girard,Pierre Grammond,Michael Barnett,Grace Stewart,Marco Onofrj,Guillermo Izquierdo,Sara Eichau,Francois Grand'Maison,Julie Prevost,Bart Van Wijmeersch,Maria Pia Amato,Vahid Shaygannejad,Cavit Boz,Ricardo Fernandez Bolaños,Aysun Soysal,Cristina Ramo-Tello,Claudio Solaro,Claudio Gobbi,Jose Antonio Cabrera-Gomez,Etienne Roullet,Cees Zwanikken,Leontien Den Braber-Moerland,Norma Deri,Maria Laura Saladino,Edgardo Cristiano,Juan Ignacio Rojas,Carlos Vrech,Cameron Shaw,Neil Shuey,Mike Boggild,Ik Lin Tan,Todd Hardy,Danny Decoo,Fraser Moore,Jiwon Oh,Patrice Lalive,Radek Ampapa,Thor Petersen,Celia Oreja-Guevara,Angel Perez Sempere,Jose Andres Dominguez,Sarah Besora,Stella Hughes,Orla Gray,Nikolaos Grigoriadis,Imre Piroska,Csilla Rozsa,Krisztian Kasa,Magdolna Simo,Krisztina Kovacs,Attila Sas,Eniko Dobos,Cecilia Rajda,Chris McGuigan,Deborah Mason,Jan Schepel,Jabir Alkhaboori,Maria Edite Rio,Simu Mihaela,Talal Al-Harbi,Ayse Altintas,Ilya Kister,Mark Marriott,Trevor Kilpatrick,John King,Ai-Lan Nguyen,Chris Dwyer,Mastura Monif,Lisa Taylor,Matteo Diamanti,Clara Chisari,Simona Toscano,Lo Fermo Salvatore,Catherine Larochelle,Giovanna De Luca,Valeria Di Tommaso,Daniela Travaglini,Erika Pietrolongo,Maria di Ioia,Deborah Farina,Luca Mancinelli,Raymond Hupperts,Javier Olascoaga,Albert Saiz,Robert Zivadinov,Ralph Benedict,Freek Verheul,Marzena Fabis-Pedrini
DOI: https://doi.org/10.1001/jamaneurol.2023.1184
2023-07-01
Abstract:Importance: Autologous hematopoietic stem cell transplant (AHSCT) is available for treatment of highly active multiple sclerosis (MS). Objective: To compare the effectiveness of AHSCT vs fingolimod, natalizumab, and ocrelizumab in relapsing-remitting MS by emulating pairwise trials. Design, setting, and participants: This comparative treatment effectiveness study included 6 specialist MS centers with AHSCT programs and international MSBase registry between 2006 and 2021. The study included patients with relapsing-remitting MS treated with AHSCT, fingolimod, natalizumab, or ocrelizumab with 2 or more years study follow-up including 2 or more disability assessments. Patients were matched on a propensity score derived from clinical and demographic characteristics. Exposure: AHSCT vs fingolimod, natalizumab, or ocrelizumab. Main outcomes: Pairwise-censored groups were compared on annualized relapse rates (ARR) and freedom from relapses and 6-month confirmed Expanded Disability Status Scale (EDSS) score worsening and improvement. Results: Of 4915 individuals, 167 were treated with AHSCT; 2558, fingolimod; 1490, natalizumab; and 700, ocrelizumab. The prematch AHSCT cohort was younger and with greater disability than the fingolimod, natalizumab, and ocrelizumab cohorts; the matched groups were closely aligned. The proportion of women ranged from 65% to 70%, and the mean (SD) age ranged from 35.3 (9.4) to 37.1 (10.6) years. The mean (SD) disease duration ranged from 7.9 (5.6) to 8.7 (5.4) years, EDSS score ranged from 3.5 (1.6) to 3.9 (1.9), and frequency of relapses ranged from 0.77 (0.94) to 0.86 (0.89) in the preceding year. Compared with the fingolimod group (769 [30.0%]), AHSCT (144 [86.2%]) was associated with fewer relapses (ARR: mean [SD], 0.09 [0.30] vs 0.20 [0.44]), similar risk of disability worsening (hazard ratio [HR], 1.70; 95% CI, 0.91-3.17), and higher chance of disability improvement (HR, 2.70; 95% CI, 1.71-4.26) over 5 years. Compared with natalizumab (730 [49.0%]), AHSCT (146 [87.4%]) was associated with marginally lower ARR (mean [SD], 0.08 [0.31] vs 0.10 [0.34]), similar risk of disability worsening (HR, 1.06; 95% CI, 0.54-2.09), and higher chance of disability improvement (HR, 2.68; 95% CI, 1.72-4.18) over 5 years. AHSCT (110 [65.9%]) and ocrelizumab (343 [49.0%]) were associated with similar ARR (mean [SD], 0.09 [0.34] vs 0.06 [0.32]), disability worsening (HR, 1.77; 95% CI, 0.61-5.08), and disability improvement (HR, 1.37; 95% CI, 0.66-2.82) over 3 years. AHSCT-related mortality occurred in 1 of 159 patients (0.6%). Conclusion: In this study, the association of AHSCT with preventing relapses and facilitating recovery from disability was considerably superior to fingolimod and marginally superior to natalizumab. This study did not find evidence for difference in the effectiveness of AHSCT and ocrelizumab over a shorter available follow-up time.